Other Information.
−Removed: In July 2020, we entered into a Severance Agreement and General Release with Timothy Morris, our former Chief Financial Officer, effective as of July 8, 2020, pursuant to which Mr.
−Removed: Morris received the severance payment described in Section 6.2 of his Executive Employment Agreement effective August 14, 2017.
+Added: Nothing to report.
EXHIBIT INDEX
−Removed: Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc.
−Removed: and Timothy Morris (incorporated herein by reference to Exhibit 10.4 to the Registrants Quarterly Report on Form 10-Q filed with the Commission on August 6, 2020).
+Added: Lease Agreement dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc.
+Added: and ARE-San Francisco No.
+Added: 63, LLC (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021).
+Added: Second Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc.
+Added: and Hudson Skyway Landing, LLC (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021).
+Added: First Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc.
+Added: and Hudson Skyway Landing, LLC (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021).
+Added: Executive Employment Agreement, effective as of March 15, 2021, by and between Igor Bilinsky, Ph.D.
+Added: and Iovance Biotherapeutics, Inc.
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
3 unchanged sentences
The following financial information from the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc.
−Removed: for the quarter ended September 30, 2020, formatted in iXBRL (Inline eXtensible Business Reporting Language):
−Removed: (1) Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019;
−Removed: (2) Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019;
−Removed: (3) Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019;
−Removed: (4) Condensed Consolidated Statements of Stockholders’ Equity as of September 30, 2020 and December 31, 2019;
−Removed: (5) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019;
+Added: for the quarter ended March 31, 2021, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: (1) Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020;
+Added: (2) Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020;
+Added: (3) Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2021 and 2020;
+Added: (4) Condensed Consolidated Statements of Stockholders’ Equity as of March 31, 2021 and December 31, 2020;
+Added: (5) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020;
and (6) Notes to Condensed Consolidated Financial Statements.
Cover Page Interactive Data File – the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document.
−Removed: Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Indicates a management contract or compensatory plan or arrangement.
−Removed: Filed herewith.
+Added: Filed herewith (unless otherwise noted as being furnished herewith).
+Added: Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Iovance Biotherapeutics, Inc.
−Removed: November 5, 2020
/s/ Maria Fardis, Ph.D., M.B.A.
1 unchanged sentence
Chief Executive Officer (Principal Executive Officer)
−Removed: November 5, 2020
−Removed: /s/ Michael C.
−Removed: VP, Finance (Interim Principal Financial Officer)
+Added: /s/ Jean-Marc Bellemin
+Added: Jean-Marc Bellemin
+Added: Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.